What is Anavex Life Sciences Return-on-Tangible-Asset?
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Anavex Life Sciences's annualizedNet Income for the quarter that ended in Dec. 2023 was $-34.49 Mil. Anavex Life Sciences's average total tangible assets for the quarter that ended in Dec. 2023 was $151.23 Mil. Therefore, Anavex Life Sciences's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was -22.81%.
The historical rank and industry rank for Anavex Life Sciences's Return-on-Tangible-Asset or its related term are showing as below:
AVXL'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -257.34 Med: -79.95 Max: -28.1
Current: -28.1
During the past 13 years, Anavex Life Sciences's highest Return-on-Tangible-Asset was -28.10%. The lowest was -257.34%. And the median was -79.95%.
AVXL's Return-on-Tangible-Asset is ranked better than 59.83% of 1556
companies
in the Biotechnology industry
Industry Median: -40.005
vs AVXL: -28.10
Anavex Life Sciences Return-on-Tangible-Asset Historical Data
The historical data trend for Anavex Life Sciences's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Anavex Life Sciences Return-on-Tangible-Asset Chart
Competitive Comparison of Anavex Life Sciences's Return-on-Tangible-Asset
For the Biotechnology subindustry, Anavex Life Sciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anavex Life Sciences's Return-on-Tangible-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Anavex Life Sciences's Return-on-Tangible-Asset falls into.
Anavex Life Sciences Return-on-Tangible-Asset Calculation
Anavex Life Sciences's annualized Return-on-Tangible-Asset for the fiscal year that ended in Sep. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2023) net income data.
Anavex Life Sciences (NAS:AVXL) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Anavex Life Sciences Return-on-Tangible-Asset Related Terms
Thank you for viewing the detailed overview of Anavex Life Sciences's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Anavex Life Sciences (Anavex Life Sciences) Business Description
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AVXL has been successfully added to your 